NO863253L - Fremgangsmaate for fremstilling av et vandig vaeskeformig preparat. - Google Patents

Fremgangsmaate for fremstilling av et vandig vaeskeformig preparat.

Info

Publication number
NO863253L
NO863253L NO863253A NO863253A NO863253L NO 863253 L NO863253 L NO 863253L NO 863253 A NO863253 A NO 863253A NO 863253 A NO863253 A NO 863253A NO 863253 L NO863253 L NO 863253L
Authority
NO
Norway
Prior art keywords
preparation
aqueous liquid
procedure
irritation
compound
Prior art date
Application number
NO863253A
Other languages
English (en)
Other versions
NO171005C (no
NO863253D0 (no
NO171005B (no
Inventor
Hisayoshi Shimizu
Missuaki Oshima
Hideo Terayama
Original Assignee
Takeda Chemical Industries Ltd
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Senju Pharma Co filed Critical Takeda Chemical Industries Ltd
Publication of NO863253D0 publication Critical patent/NO863253D0/no
Publication of NO863253L publication Critical patent/NO863253L/no
Publication of NO171005B publication Critical patent/NO171005B/no
Publication of NO171005C publication Critical patent/NO171005C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO863253A 1985-08-19 1986-08-12 Fremgangsmaate for fremstilling av et vandig flytende preparat NO171005C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18238385 1985-08-19

Publications (4)

Publication Number Publication Date
NO863253D0 NO863253D0 (no) 1986-08-12
NO863253L true NO863253L (no) 1987-02-20
NO171005B NO171005B (no) 1992-10-05
NO171005C NO171005C (no) 1993-01-13

Family

ID=16117350

Family Applications (1)

Application Number Title Priority Date Filing Date
NO863253A NO171005C (no) 1985-08-19 1986-08-12 Fremgangsmaate for fremstilling av et vandig flytende preparat

Country Status (10)

Country Link
US (1) US4728509A (no)
EP (1) EP0213514B1 (no)
JP (1) JPS62123116A (no)
AT (1) ATE53944T1 (no)
CA (1) CA1269618A (no)
DE (1) DE3672097D1 (no)
DK (1) DK166757B1 (no)
IE (1) IE59425B1 (no)
MY (1) MY102075A (no)
NO (1) NO171005C (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940701A (en) * 1984-01-25 1990-07-10 Beecham Group P.L.C. Topical drug release system
GB8629639D0 (en) * 1986-12-11 1987-01-21 Beecham Group Plc Composition & method
GB8629640D0 (en) * 1986-12-11 1987-01-21 Beecham Group Plc Composition & method
US4778810A (en) * 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
ES2012532A6 (es) * 1988-07-15 1990-04-01 Cusi Lab Un procedimiento para la preparacion de una solucion acuosa de b-metil-4-(2' -tienilcarbonil)fenilacetato de lisina para aplicacion topica oftalmica.
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH0714872B2 (ja) * 1990-02-06 1995-02-22 昭和薬品化工株式会社 シロップ剤組成物
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
EP0621036B1 (en) * 1993-04-22 1999-03-17 Senju Pharmaceutical Co., Ltd. Aqueous compositions comprising argatroban and cyclodextrin or caffeine
US5519030A (en) * 1993-10-07 1996-05-21 Senju Pharmaceutical Co., Ltd. Method for prophylaxis and treatment of myopia
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
KR980008226A (ko) * 1996-07-05 1998-04-30 다케다 쿠니오 시각기능장애의 예방 및 치료제
PT986403E (pt) * 1997-06-13 2004-04-30 Cydex Inc Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
EP1109581A1 (en) 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
JP2001125052A (ja) * 1999-10-25 2001-05-11 Lion Corp コンタクトレンズ装着液
US20030152631A1 (en) * 2000-06-19 2003-08-14 Santen Pharmaceutical Co., Ltd. Aseptics
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
SI2377557T1 (sl) 2004-11-24 2017-02-28 Meda Pharmaceuticals Inc. Sestavki, ki obsegajo azelastin, in postopki njihove uporabe
MX2007010906A (es) 2005-03-10 2007-12-05 3M Innovative Properties Co Metodos para reducir la contaminacion microbiana.
US20070010478A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009531A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
HUE046071T2 (hu) * 2009-10-30 2020-01-28 Intratus Inc Eljárások és készítmények gyógyszerek elnyújtott hatóanyagleadására
MX2013000578A (es) * 2010-07-21 2013-02-21 Alcon Res Ltd Composicion farmaceutica con caracteristicas de solubilidad incrementadas.
EP2675275B1 (en) 2011-02-14 2017-12-20 The Regents Of The University Of Michigan Compositions and methods for the treatment of obesity and related disorders
US9492552B2 (en) * 2011-11-29 2016-11-15 Jurox Pty Ltd Injectable aqueous pharmaceutical compositions comprising a cyclodextrin, a hydrophobic drug, a co-solvent, and a preservative
EP2991647B1 (en) 2013-05-02 2019-04-24 The Regents Of The University Of Michigan Deuterated amlexanox with improved metabolic stability
US10214536B2 (en) 2016-01-29 2019-02-26 The Regents Of The University Of Michigan Amlexanox analogs
ES2914305T3 (es) * 2017-12-26 2022-06-09 Ind Tech Res Inst Composición para mejorar la solubilidad de sustancias poco solubles, uso de la misma y formulación compleja que contiene la misma

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD7498A1 (de) * 1951-02-20 1954-05-31 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung von haltbaren Lösungen in 1,3-Stellung substituierter Xanthine
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
JPS53111096A (en) * 1977-03-08 1978-09-28 Takeda Chem Ind Ltd 1-azaxanthone-3-carboxylic acid derivative and its preparation
AU513456B2 (en) * 1977-03-08 1980-12-04 Takeda Chemical Industries Ltd. l-Azaxanthone-3-carboxylic acids
JPS54115398A (en) * 1978-02-27 1979-09-07 Takeda Chem Ind Ltd 1-azaxanthone-3-carboxylic acid derivative and its preparation
JPS6042766B2 (ja) * 1978-12-09 1985-09-25 日本化薬株式会社 基剤
ZA815175B (en) * 1980-08-01 1982-09-29 Smith & Nephew Ass Pharmaceutical composition
JPS57200361A (en) * 1981-06-03 1982-12-08 Sumitomo Chem Co Ltd "indomethacin(r)" pharmaceutical with low irritant action
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
JPS58174310A (ja) * 1982-04-06 1983-10-13 Wakamoto Pharmaceut Co Ltd 抗炎症点眼剤
DE3372705D1 (en) * 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
US4539326A (en) * 1982-08-20 1985-09-03 Takeda Chemical Industries, Ltd. 5-Oxo-5H-(1)benzopyrano(2,3-b)pyridine derivatives, their production and use as anti-inflammatory agents
US4559343A (en) * 1982-09-07 1985-12-17 Alcon Laboratories, Inc. Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents
JPS59106424A (ja) * 1982-12-09 1984-06-20 Kyorin Pharmaceut Co Ltd 易吸収性キノリンカルボン酸誘導体組成物およびその製剤
JPS59152320A (ja) * 1983-02-17 1984-08-31 Takeda Chem Ind Ltd 水性製剤
KR920010047B1 (ko) * 1985-01-28 1992-11-13 다께다야꾸힝고오교 가부시끼가이샤 2-아미노-5-옥소-5H-[1]벤조피라노[2,3-b]피리딘-3-카르복실산 유도체의 제조방법

Also Published As

Publication number Publication date
ATE53944T1 (de) 1990-07-15
MY102075A (en) 1992-03-31
EP0213514B1 (en) 1990-06-20
JPS62123116A (ja) 1987-06-04
US4728509A (en) 1988-03-01
NO171005C (no) 1993-01-13
DK379986A (da) 1987-02-20
DE3672097D1 (de) 1990-07-26
JPH0478614B2 (no) 1992-12-11
DK379986D0 (da) 1986-08-08
EP0213514A3 (en) 1987-07-22
NO863253D0 (no) 1986-08-12
IE59425B1 (en) 1994-02-23
IE862214L (en) 1987-02-19
NO171005B (no) 1992-10-05
CA1269618A (en) 1990-05-29
EP0213514A2 (en) 1987-03-11
DK166757B1 (da) 1993-07-12

Similar Documents

Publication Publication Date Title
NO863253D0 (no) Fremgangsmaate for fremstilling av et vandig vaeskeformig preparat.
NO992549L (no) Sukkerforbindelse, geleringsmiddel og fremgangsmåte for fremstilling derav
JPS5297950A (en) Chalconeether derivatives
NO882626D0 (no) Fremgangsmaate for fremstilling av farmakologisk aktive pyridin-derivater.
PT83104A (en) Novel guanidinomethylbenzoic acid derivatives
DE3879258D1 (de) Praeparat gegen ulcus.
ES2074992T3 (es) Derivados fungicidas de azolilo.
JPS5424829A (en) Organic phosphate compound, its preparation, and insecticide, miticide and nematocide containing the same
JPS5225740A (en) Preparation of o-acyl-amidinophenols or acid addition salts thereof
GB2071098B (en) Dibenzocycloheptenylidenes and antiinflammatory compositions
JPS5239674A (en) Imidazole derivatives and agricultural bactericides therefrom
DK232883D0 (da) Fremgangsmade til fremstilling af optisk aktive imidazolylpropanolforbindelser
JPS5283571A (en) Glutarimide derivatives
DK601883A (da) Phenyl-propanolderivater
AU2639388A (en) 2-cyano-2-aryl-1-(azole-1-yl)- ethane derivatives
JPS53147017A (en) Compound of acylketene-s.n-acetal and its preparation
JPS5283672A (en) Novel 2-amino-1,4-dihydropyridine derivatives
JPS52130820A (en) Production of tetrachloronaphthalic acid derivative
JPS5283559A (en) 2-substituted-1,3-diazacycloalkanes
JPS52113970A (en) Thiadiazoline-type organic phosphates, their preparation, and insectic ide or miticide containing the same
JPS52118470A (en) Dithiolane derivatives
JPS5285154A (en) 4-alkyl-4 -biphenylcarboxylic acids
JPS5289621A (en) 2-sulfonyloxyethylphosphonic acid derivatives
ATE36536T1 (de) Phosphoroimidate.
JPS53124276A (en) Uracil derivatives